Simparica is a veterinary antiparasitic brand developed and marketed by Zoetis. Its principal product, Simparica (sarolaner), is a flavored chewable oral medicine for dogs used primarily to control fleas and ticks. The brand belongs to the isoxazoline class of antiparasitic medicines. 1

A closely related product, Simparica Trio, combines sarolaner with moxidectin and pyrantel to provide broader protection against external and internal parasites.

Note: Simparica products and approved indications vary by country. The information below is primarily based on U.S. FDA and European regulatory information and should not be interpreted as a substitute for a veterinarian’s advice.

Simparica is a brand of canine parasiticide. The original Simparica product contains sarolaner, a synthetic compound belonging to the isoxazoline family.

Sarolaner works primarily against arthropod parasites such as fleas and ticks. Regulatory documentation describes Simparica as providing rapid and persistent flea- and tick-killing activity. In the European product information, for example, the product is indicated against several tick species and Ctenocephalides fleas, with activity lasting at least several weeks after administration.

The basic concept is straightforward:

Dog takes chewable tablet → sarolaner enters the dog’s bloodstream → feeding fleas/ticks are exposed to the drug → parasite nervous-system function is disrupted → parasite dies.

Simparica is produced by Zoetis, one of the world’s major animal-health companies.

Zoetis specializes in medicines, vaccines, diagnostics and other products for companion animals and livestock. Simparica is part of its companion-animal parasiticide portfolio, alongside products addressing other types of parasite protection.

The original Simparica was followed by Simparica Trio, reflecting Zoetis’s move toward broader, combination parasite protection. Zoetis describes Simparica Trio as a once-monthly combination parasiticide containing sarolaner, moxidectin and pyrantel.

The key ingredient in standard Simparica is sarolaner.

Sarolaner belongs to the isoxazoline class. This class includes several modern flea-and-tick medications used in veterinary medicine.

Rather than acting like a traditional insecticide applied externally to the animal’s coat, sarolaner is administered systemically. A flea or tick must feed on the treated animal and become exposed to the drug.

The FDA identifies sarolaner as an isoxazoline and notes that it was first approved in the United States in 2016 for treating and controlling flea and tick infestations.

At the pharmacological level, isoxazolines interfere with ligand-gated chloride channels in the nervous system of susceptible parasites.

This causes abnormal neuronal activity in the parasite, eventually resulting in paralysis and death.

The important distinction is that the drug’s target is particularly relevant to arthropod nervous systems. This allows isoxazolines to be used therapeutically in dogs at appropriate doses.

Requirement for feeding

Simparica isn’t primarily a repellent. Its mechanism relies on the parasite being exposed to sarolaner after feeding on the treated dog.

Consequently, killing a tick does not necessarily mean that the tick was prevented from making initial contact with the dog. This distinction is important when discussing tick-borne diseases.

The exact approved indications depend on the country and product version.

For the standard European Simparica formulation, the product information includes:

• Fleas
• Ticks
• Sarcoptic mange (Sarcoptes scabiei)
• Flea Allergy Dermatitis as part of a treatment strategy

The European product information lists activity against multiple tick species, including Dermacentor, Ixodes and Rhipicephalus species. 3

In the United States, Simparica is principally positioned as a flea-and-tick product.

This is why it is important not to assume that “Simparica” means exactly the same thing in every country.

This is one of the most important distinctions within the brand.

Simparica

Active ingredient:

Sarolaner

Primarily provides protection against fleas and ticks, with additional indications varying by jurisdiction.

Simparica Trio

Active ingredients:

Sarolaner + moxidectin + pyrantel

It expands the spectrum considerably.

In the United States, FDA-approved indications include:

• Prevention of heartworm disease
• Treatment/control of certain roundworms
• Treatment/control of certain hookworms
• Treatment/prevention of flea infestations
• Treatment/control of several tick species
• Prevention of Borrelia burgdorferi infection as a direct result of killing Ixodes scapularis vector ticks
• Prevention of Dipylidium caninum infection as a direct result of killing vector fleas

The FDA currently specifies these indications for dogs and puppies 8 weeks of age or older and weighing at least 2.8 lb (1.27 kg) for the U.S. product.

Ingredient roles

The FDA describes these as three previously established antiparasitic ingredients brought together into one combination product.

The development of Simparica fits into the broader evolution of modern veterinary flea-and-tick medicines.

2016 — Sarolaner approval

The FDA approved sarolaner for flea and tick treatment/control in dogs in 2016, establishing the foundation for the Simparica product.

2019 — Simparica Trio in Europe

The European Commission granted marketing authorization for Simparica Trio in September 2019. The combination contained sarolaner, moxidectin and pyrantel and was intended to address both external and internal parasites.

2020 — U.S. approval of Simparica Trio

The FDA approved Simparica Trio in March 2020.

It was introduced as a monthly chewable combining protection against heartworm disease, fleas, ticks, roundworms and hookworms.

2022 — Lyme-related indication

In 2022, the FDA approved an additional indication for Simparica Trio relating to prevention of Borrelia burgdorferi infection through killing Ixodes scapularis ticks.

2024 — Asian longhorned tick

The U.S. label was subsequently expanded to include treatment and control of Haemaphysalis longicornis, commonly called the Asian longhorned tick.

2025 — Flea tapeworm indication

In 2025, the FDA approved a new indication for Simparica Trio to prevent Dipylidium caninum tapeworm infection as a direct result of killing Ctenocephalides felis vector fleas.

2026 — New World screwworm authorization

A notable recent development occurred in August 2026. The FDA issued an Emergency Use Authorization (EUA) for Simparica Trio to treat infestations caused by New World screwworm larvae (Cochliomyia hominivorax) in dogs and puppies. This is an emergency authorization and should not be confused with the product’s ordinary parasite-prevention indications. 4

Simparica is administered orally as a chewable tablet.

The European formulation, for example, is available in several sarolaner strengths corresponding to different dog-weight ranges:

• 5 mg
• 10 mg
• 20 mg
• 40 mg
• 80 mg
• 120 mg

The tablets are designed for dogs in different weight categories.

The precise dose and schedule should always follow the product label for the country where the product is being used and the veterinarian’s instructions.

A major selling point of the product family is convenience.

Instead of repeatedly applying topical flea/tick products or administering multiple separate parasite medicines, an owner can give an appropriately dosed chewable on a recurring schedule.

For Simparica Trio in the United States, the FDA describes the product as a once-monthly medication.

Some international Simparica labeling describes persistent flea/tick activity extending for several weeks, so the precise duration should be taken from the relevant local label rather than generalized across every market.

Simparica is generally considered an effective veterinary antiparasitic when used according to its approved labeling, but it is not completely risk-free.

The most important safety issue associated with sarolaner and other isoxazolines is the possibility of neurological adverse reactions.

The FDA specifically warns that isoxazoline products, including Simparica, have been associated in some animals with:

• Muscle tremors
• Ataxia/loss of coordination
• Seizures

These events have been reported in animals with and without previous neurological disorders.

This does not mean that most dogs receiving Simparica will experience seizures. Rather, it is an established safety consideration that veterinarians and owners should know about.

For Simparica Trio, FDA safety information also lists adverse reactions observed in clinical studies including vomiting, diarrhea, lethargy, decreased appetite, itching and other events.

If a dog develops unusual neurological signs or another significant reaction after receiving the medication, veterinary advice should be sought promptly.

Because sarolaner belongs to the isoxazoline class, extra caution is appropriate in dogs with a history of seizures or neurological disorders.

This doesn’t automatically mean that every dog with such a history cannot receive an isoxazoline. The appropriate decision depends on the individual animal, its medical history and the alternatives available.

For Simparica Trio, Zoetis explicitly advises caution in dogs with a history of seizures.

A common misconception is that standard Simparica and Simparica Trio are interchangeable.

They aren’t.

Standard Simparica’s primary role is flea/tick control. Simparica Trio, because it contains moxidectin, also provides heartworm prevention in markets where that indication is approved.

Therefore:

Simparica ≠ Simparica Trio

A veterinarian should determine which parasite-control coverage a particular dog needs.

Ticks are medically important because they can transmit pathogens to dogs.

Simparica’s sarolaner component kills susceptible ticks after they become exposed to the drug.

Simparica Trio has approved activity against several tick species in the United States, including:

• Lone star tick
• Gulf Coast tick
• American dog tick
• Black-legged/deer tick
• Brown dog tick
• Asian longhorned tick

The exact list varies by regulatory jurisdiction and can change as new indications are approved.

Fleas are another major target.

Beyond causing itching and skin irritation, fleas can contribute to flea allergy dermatitis and can act as vectors for certain parasites.

Simparica kills adult fleas, while Simparica Trio’s U.S. label also includes prevention of Dipylidium caninum infection through killing Ctenocephalides felis vector fleas.

From a veterinary-product perspective, Simparica’s major advantages include:

• Oral administration rather than a topical treatment.
• Convenient recurring dosing.
• Rapid activity against fleas and ticks.
• A well-established active ingredient in the isoxazoline class.
• Availability of Simparica Trio for dogs requiring broader parasite coverage.
• Integration of multiple parasite treatments into one chewable in the Trio formulation.

Simparica Trio was recognized as Best Companion Animal Product in the 2020 Animal Health Awards. 2

Simparica is a veterinary medicinal product, not a human medicine.

In the United States, Simparica products are regulated by the FDA Center for Veterinary Medicine (CVM).

Simparica Trio was approved by the FDA in 2020, and its labeling has subsequently been expanded through additional approvals.

As of 2026, the product has therefore evolved considerably from its original flea-and-tick positioning, particularly through the Simparica Trio line.

From a branding/product-strategy perspective, Simparica can be understood as a canine parasite-protection platform rather than simply one tablet.

The portfolio has essentially developed along this path:

Simparica → flea & tick protection

↓

Simparica Trio → flea + tick + heartworm + selected intestinal parasites

↓

Additional label expansions → increasingly broad parasite coverage

This strategy allows Zoetis to address different levels of parasite-control needs while keeping sarolaner as the common flea/tick component.

Simparica is a Zoetis veterinary parasiticide brand centered on sarolaner, an isoxazoline drug used primarily for flea and tick control in dogs. It became particularly notable because of its oral chewable format and recurring protection.

Its companion product, Simparica Trio, takes the concept considerably further by combining sarolaner + moxidectin + pyrantel, allowing one monthly chewable to address fleas, ticks, heartworm and several intestinal parasites in accordance with its local label.

The brand is now a significant part of Zoetis’s companion-animal parasite-control portfolio. At the same time, the isoxazoline class carries a recognized potential for neurological adverse reactions, so product selection should be individualized—particularly for dogs with a history of seizures or neurological disease.

1. Simparica – CVMP PI
2. FDA Approves Simparica Trio, a Combination Drug for Heartworm and Other Parasites
3. Simparica Trio Wins “Best Companion Animal Product
4. Fact Sheet for Veterinarians: Emergency Use Authorization of Simparica TRIO (sarolaner, moxidectin, and pyrantel…